Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...
Private health insurance premiums will be going up in 2026 — in some cases, by a lot. Congressional Democrats and Republicans ...
6don MSN
Notable healthcare headlines for the week: UnitedHealth, Eli Lilly, and Bristol Myers in focus
Wall Street's major averages closed in the green on Friday, as traders assessed fresh inflation data in hopes of gauging the Federal Reserve's monetary policy. The benchmark S&P 500 closed +0.2%, ...
Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...
Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply ...
Some patients dropped out of the trial early because they had lost so much weight.
Eli Lilly highlighted its drug's effectiveness in helping people lose weight. Pharmaceutical giant Eli Lilly that new preliminary research indicates its medication Zepbound helps patients lose more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback